GILD Technical Analysis
As of date:2/6/2023
GILD stock price:86.36
GILD 50 DMA:85.58
GILD 200 DMA:69.39
GILD MACD (200-50):-16.19
GILD RSI:53.76
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)53.76
Extremely
Oversold

Also see:
GILD Market Cap History
GILD Shares Outstanding History
GILD YTD Return

Quotes delayed 20 minutes

Email EnvelopeFree GILD Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Bullish Two Hundred Day Moving Average Cross - VNOM
1 hour, 9 minutes ago


Alpine Immune Sciences Breaks Below 200-Day Moving Average - Notable for ALPN
1 hour, 9 minutes ago


Notable Two Hundred Day Moving Average Cross - NAAS
1 hour, 9 minutes ago


Casella Waste Systems (CWST) Shares Cross Below 200 DMA
1 hour, 23 minutes ago


DTC Makes Notable Cross Below Critical Moving Average
1 hour, 31 minutes ago


HII Makes Bullish Cross Above Critical Moving Average
1 hour, 32 minutes ago


Bullish Two Hundred Day Moving Average Cross - PXI
1 hour, 32 minutes ago


Bullish Two Hundred Day Moving Average Cross - MKP.CA
1 hour, 35 minutes ago


Shares of TAIL Now Oversold
1 hour, 35 minutes ago


Bullish Two Hundred Day Moving Average Cross - POU.CA
1 hour, 35 minutes ago


Bullish Two Hundred Day Moving Average Cross - BRO
1 hour, 35 minutes ago


Enact Holdings Breaks Below 200-Day Moving Average - Notable for ACT
5 hours, 54 minutes ago


RXRX Makes Notable Cross Below Critical Moving Average
5 hours, 57 minutes ago


Zumiez (ZUMZ) Shares Cross Below 200 DMA
5 hours, 58 minutes ago


A-Mark Precious Metals (AMRK) Shares Cross Below 200 DMA
5 hours, 58 minutes ago


More Technical Analysis News

GILD Technical AnalysisGILD RSI
Gilead Sciences is a biopharmaceutical company, focusing on medicines to prevent and treat diseases, including HIV, viral hepatitis and cancer. Co.'s products include: Biktarvy®, which is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), an injection for intravenous use, which is a nucleotide analog RNA polymerase inhibitor indicated for certain patients for the treatment of COVID-19 requiring hospitalization; and Epclusa®, which is an oral formulation of a once-daily single tablet regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus (HCV) infection in adults and certain pediatric patients.

When researching a stock like Gilead Sciences, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from GILD Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for GILD stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
GILD DMAGILD MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Gilead Sciences (GILD) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

HCA Technical Analysis
HOLX Technical Analysis
HSIC Technical Analysis
IDXX Technical Analysis
ILMN Technical Analysis
INCY Technical Analysis
IQV Technical Analysis
ISRG Technical Analysis
JNJ Technical Analysis
LH Technical Analysis
More Healthcare companies »

 

GILD Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2023, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.